nanoparticle

1,2-Distearoyl-sn-glycero-3-phosphorylcholine (L-ALPHA-PHOSPHATIDYLCHOLINE, DISTEAROYL) is a cylindrical-shaped lipid used to synthesize liposomes. 1,2-Distearoyl-sn-glycero-3-phosphorylcholine (L-ALPHA-PHOSPHATIDYLCHOLINE, DISTEAROYL) is the lipid component in the lipid nanoparticle (LNP) system.

PLGA nanoparticles, 100 nm, are nanocarriers composed of the polymer PLGA, which can be utilized for drug delivery.

PLGA nanoparticles, 500 nm, are nanoscale particles composed of the polymer PLGA, utilized in drug delivery systems.

PLGA nanoparticles (500 nm) are polymer-based particles made from PLGA, utilized for drug delivery.

PLGA nanoparticles, measuring 1μm, are polymer-based particles crafted from PLGA, suitable for drug delivery applications.

SM-102 is the only ionizable amino cationic lipid currently clinically approved for RNA therapeutics and can be used to synthesize lipid nanoparticles (LNPs). It shows potential in the development of LNPs for the delivery of mRNA-based vaccines.

BAMEAO16B is a lipid nanoparticle that incorporates disulfide bonds for efficient delivery of Cas9 mRNA and sgRNA into cells. In the intracellular environment, BAMEAO16B responds to reduction by releasing RNA, facilitating genome editing. This compound is valuable for gene editing research purposes.

TCL053, an ionizable lipid carrier, efficiently facilitates the introduction of active components, particularly nucleic acids, into cells. In combination with Dipalmitoylphosphatidylcholine (DPPC), Polyethylene glycol dimyristoyl glycerol (PEG-DMG), and cholesterol, TCL053 composes a lipid nanoparticle (LNP) system capable of delivering Cas9 mRNA and sgRNA into skeletal muscle [1] [2].

Heptadecan-9-yl 8-((6-(decyloxy)-6-oxohexyl)(2-hydroxyethyl)amino)octanoate is employed in lipid nanoparticle (LNP) delivery systems for mRNA vaccine delivery [1].

306-N16B is a lipid nanoparticle designed for the systemic co-delivery of Cas9 mRNA and sgRNA, facilitating the transport of mRNA to pulmonary endothelial cells. This compound is advantageous for research focused on genome editing-based therapies [1].

Phospholipid PL1, a phospholipid-derived nanoparticle, efficiently delivers costimulatory receptor mRNA (CD137 or OX40) to T cells, thereby inducing the activation of immune cells such as T cells and dendritic cells (DCs) to enhance antitumor immunity [1].

LNP Lipid-4 (Compound 8-8) is a lipid compound integral to the synthesis of lipid nanoparticle compositions, demonstrating potential for the transport of biologically active substances [1].

CD19 car mRNA-LNP, a lipid nanoparticle (LNP) encapsulating CD19 car mRNA, is instrumental in assessing RNA delivery, translation efficacy, and cell viability among other applications. This compound is pivotal for chimeric antigen receptor T cell immunotherapy (CAR-CD19), leveraging the CD19 molecule - a critical membrane antigen expressed by B cells (i.e., leukocyte differentiation antigen) that plays a significant role in their proliferation, differentiation, activation, and antibody production, as well as enhancing BCR signal transduction [1] [2].

CD19 car circRNA-LNP, a lipid nanoparticle containing CD19 car circRNA, is designed for applications in RNA delivery, translation efficiency, and cell viability assessment. This compound is utilized in chimeric antigen receptor T cell immunotherapy (CAR-CD19), leveraging CD19 car, a chimeric antigen receptor that targets CD19. CD19, a CD molecule found on B cells (i.e., leukocyte differentiation antigen), plays a crucial role in B cell proliferation, differentiation, activation, and antibody production by facilitating BCR signal transduction [1] [2].

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) formulated with the novel coronavirus pneumonia spike protein, positioned on the membrane surface. It is designed for applications such as RNA delivery, translation efficiency, and cell viability assessment. This spike protein facilitates the COVID-19 virus's entry into host cells by binding to cell membrane receptors and enabling membrane fusion, making it a critical focal point for host neutralizing antibodies and vaccine development [1].

Genevant CL1 is a lipid that can be used for mRNA lipid nanoparticle (LNP) vaccine delivery [1] .

C13-113-tri tail, a cationic lipid-like compound, features a polar amino alcohol head group, three hydrophobic carbon-13 tails, and a tertiary amine linker. It is capable of being formulated into a lipid nanoparticle (LNP).

C13-113-tetra tail, a cationic lipid-like compound, features a polar amino alcohol head group, a tertiary amine linker, and four hydrophobic carbon-13 tails. It can be formulated into a lipid nanoparticle (LNP).

C14-4 (C14-494) is an ionizable lipid nanoparticle used for delivering CAR mRNA to primary human T cells.

Trimethyl chitosan (N,N,N-Trimethylchitosan), a derivative of Chitosan, is a water-soluble, multifunctional polymer utilized in drug delivery and nanoparticle synthesis [1].

DMG-PEG 2000 (DMG-PEG2000) is a lipid excipient that has been used in combination with other lipids in the formation of lipid nanoparticles. Formulations containing DMG-PEG 2000 have been used in the development of lipid nanoparticles for the delivery of mRNA-based vaccines.

D-Erythro-sphingosyl phosphoinositol is a lipid nanoparticle covalently linked to antibodies, with potential for targeted compound delivery. It enhances compound accumulation in specific cell types and may serve as a ligand to boost antibody efficacy in immunosuppression. Additionally, D-Erythro-sphingosyl phosphoinositol can be utilized for studying mechanisms related to cell signaling and lipid metabolism.

PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a PLGA-PEG-Mal nanoparticle comprising poly(lactic-co-glycolic acid) and polyethylene glycol blocks. Its molecular weight is 60kDA-3.4kDA, with a composition ratio of lactic acid (LA) to glycolic acid (GA) molecules at 75:25.

PEG2000-DGG is a synthetic lipid used in lipid-based nanoparticle (LNP) delivery systems.